Amivantamab with lazertinib emerges as a promising frontline therapy for EGFR-mutated metastatic NSCLC, enhancing overall survival and treatment tolerability.
Kevin Leffers, PharmD
Advertisement
Articles by Kevin Leffers, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
Meet the FDA’s Newly Approved OTC Sunscreen Ingredient: Bemotrizinol
4
Melatonin May Reduce Musculoskeletal Pain and Improve Sleep
5